Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

PURPOSE: Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. Fulvestrant exhibits e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Wardell, Suzanne E., Yllanes, Alexander P., Chao, Christina A., Bae, Yeeun, Andreano, Kaitlyn J., Desautels, Taylor K., Heetderks, Kendall A., Blitzer, Jeremy T., Norris, John D., McDonnell, Donald P.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Preclinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985185/
https://ncbi.nlm.nih.gov/pubmed/31562570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05454-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados